The US Department of Defense Chemical and Biological Defense Program (CBDP) has awarded Australian pharma company ENA Respiratory $4.38 million for development of a dry powder formulation of the company's INNA-051 intranasal pegylated TLR2/6 agonist for protection against a wide range of respiratory viruses, ENA said. According to ENA, the 12-month project is expected … [Read more...] about ENA Respiratory gets $4.38 million from US Department of Defense for development of dry powder intranasal formulation of INNA-051
Business
Lupin launches Difizma triple combination DPI in India
Lupin announced that it has launched its Difizma indacaterol / glycopyrronium / mometasone DPI in India for the treatment of inadequately controlled asthma. The company says that Difizma is the first fixed dose combination approved for the treatment of poorly controlled asthma by the Drug Controller General of India (DCGI). In 2022, Glenmark launched an indacaterol … [Read more...] about Lupin launches Difizma triple combination DPI in India
Acorda Therapeutics announces new supply agreement with Catalent for manufacture of Inbrija inhaled dry powder levodopa
Acorda Therapeutics announced that it has signed a new supply agreement with Catalent that reduces the amount of product that the company is required to buy annually from $18 million to $8.5 million for 2023 and $15.5 million for 2024. From 2025 on, the announcement says, Acorda will pay a fixed amount per capsule "based on the amount of Inbrija needed in the US and … [Read more...] about Acorda Therapeutics announces new supply agreement with Catalent for manufacture of Inbrija inhaled dry powder levodopa
Cipla invests €15 million in inhaled mRNA developer Ethris
Cipla has announced a €15 million equity investment in inhaled mRNA developer Ethris. In February 2022, Ethris announced that it had closed a $26.3 million Series B financing round with proceeds going to support its ETH47 nebulized antiviral and ETH42 inhaled therapy for the treatment of primary ciliary dyskinesia. The company is also developing an inhaled mRNA … [Read more...] about Cipla invests €15 million in inhaled mRNA developer Ethris
Researchers at the Centenary Institute and the University of Sydney get grant of almost AU$1 million for development of intranasal vaccine against COVID-19
According to the Centenary Institute, the New South Wales COVID-19 Vaccine Acceleration Research Grants Program has awarded a grant worth AU$995,867 to researchers at the Centenary Institute and the University of Sydney to support development of an intranasal vaccine against COVID-19. Sydney-based Ab Initio Pharma, which was recently granted a license to manufacture … [Read more...] about Researchers at the Centenary Institute and the University of Sydney get grant of almost AU$1 million for development of intranasal vaccine against COVID-19
Vistagen announces agreement to acquire Pherin Pharmaceuticals
Vistagen, which is developing two pherine-based nasal sprays licensed from Pherin Pharmaceuticals (PH10 and PH94B), announced that it has reached an agreement to acquire Pherin and its entire pipeline. According to Vistagen, the deal includes ~12.4 million shares of the company's common stock as well as "a nominal amount of cash." PH10 was recently granted Fast … [Read more...] about Vistagen announces agreement to acquire Pherin Pharmaceuticals
Third Pole gets $32 million to support development of eNOcare inhaled nitric oxide device
Inhaled nitric oxide (iNO) delivery device developer Third Pole Therapeutics announced that it has received a $32 million equity investment "from a large medical device innovator." In February 2022, the company announced the closing of a $25 million financing. Chiesi acquired global rights to develop and commercialize Third Pole's tankless iNO technology in April … [Read more...] about Third Pole gets $32 million to support development of eNOcare inhaled nitric oxide device
CF Foundation invests $4.85 million in Aridis Pharmaceuticals to support development of AR-501 inhaled gallium
According to Aridis Pharmaceuticals, the Cystic Fibrosis Foundation has made a $4.85 million investment in Aridis common stock to support continued development of AR-501 nebulized gallium citrate for the treatment of chronic lung infections in CF patients, bringing the CF Foundation's total funding for the project to $12.5 million. AR-501 has been granted orphan, … [Read more...] about CF Foundation invests $4.85 million in Aridis Pharmaceuticals to support development of AR-501 inhaled gallium
Evoke gets new US patent covering Gimoti metoclopramide nasal spray
According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a new patent covering Evoke's Gimoti metoclopramide nasal spray. The new patent (No. 11,517,545), which expires in 2038, is titled "Treatment of Moderate and Severe Gastroparesis." The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020 and granted 3 … [Read more...] about Evoke gets new US patent covering Gimoti metoclopramide nasal spray
Pulmocide raises $52 million for further development of inhaled opelconazole
Pulmocide announced that it has closed a $52 million a Series C extension round, with the proceeds to be used for continued development of its PC945 inhaled opelconazole for the treatment of invasive pulmonary Aspergillosis (IPA). Opelconazole has been granted orphan drug, Fast Track, and Qualified Infectious Disease Product designations. In December 2021, … [Read more...] about Pulmocide raises $52 million for further development of inhaled opelconazole